CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--HemoShear, LLC, is pleased to announce that it was awarded a Phase 1 Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH). The SBIR grant will fund the development of a rodent liver surrogate system using HemoShear’s proprietary technology platform to mimic in vivo physiology by applying liver-specific blood flow shear stress forces (hemodynamics) to a combination of liver cell types. If successful, the rodent system will provide pharmaceutical companies with a more predictive and relevant alternative to current single cell culture approaches to better understand the specific mechanism-of-action of drug efficacy and pre-clinical safety/toxicity. The work funded by this SBIR will provide the foundation for HemoShear’s development of a more advanced human liver system.
